AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

AstraZeneca PLCNYSE: AZN

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents falls 2.7% from a year ago

Cash & equivalents stood at $7.92B at the end of Q3 FY2026, down 2.7% from a year earlier and up 62.1% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.

Context

  • Cash & equivalents amounted to 6.6% of total assets at the end of Q3 FY2026, down 0.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -2.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$7.92B+62.1% QoQ
Last fiscal yearDec 2025
$5.71B+4.1% YoY
Year agoSep 2025
$8.14B-2.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.7%——
1 year+4.1%——
3-year CAGR-2.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
5.71B USD
Year-over-year change
+4.1%
4-year CAGR
-2.5%

Cash & Equivalents vs competitors

How AZN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -2.7% is the 6th highest of 10, against a peer median of +1.6%.
  • Cash & equivalents amounts to 6.6% of total assets for AZN, versus a peer median of 6.2%.
AZN Competitors
Cash & Equivalents for AZN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 44.48B DKK+141.3%+27.9%7.5%
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$8.72B USD-30.8%+3.8%10.0%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
ABBVAbbVie Inc.Jun 2026$6.57B USD+1.6%-17.2%4.9%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding AZN) —+1.6%+15.0%6.2%

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents6.33B6.17B5.84B5.49B5.71B
Short-term Investments69M77M20M37M30M
Net Receivables8.13B9.19B8.41B11.24B15.18B
Inventory8.98B4.7B5.42B5.29B6.56B
Other Current Assets1.22B1.13B3.75B2.04B1.25B
Total Current Assets26.24B22.59B25.05B25.83B28.72B
Property, Plant & Equipment (Net)10.17B9.45B10.5B11.65B14.7B
Goodwill20B19.82B20.05B21.03B21.24B
Intangible Assets42.39B39.31B38.09B37.18B37.85B
Long-term Investments001.78B02.53B
Tax Assets4.33B3.26B05.35B0
Other Non-current Assets2.23B2.05B5.65B3.01B9.04B
Total Non-current Assets79.12B73.89B76.07B78.21B85.35B
Total Assets105.36B96.48B101.12B104.04B114.07B
Account Payables2.82B2.55B3.27B3.64B25.28B
Short-term Debt1.57B5.23B5.13B2.16B3.19B
Tax Payables1.38B1.36B2.08B1.81B0
Deferred Revenue00000
Other Current Liabilities14.94B15B6.13B17.31B686M
Total Current Liabilities22.59B26.29B30.54B27.87B30.62B
Long-term Debt28.13B22.97B22.37B26.51B24.72B
Deferred Tax Liabilities6.21B2.94B31M3.31B3.51B
Deferred Revenue (Non-current)26M14M7M00
Other Non-current Liabilities8.36B6.48B8.15B4.37B5.1B
Total Non-current Liabilities43.48B33.13B31.41B35.3B34.74B
Total Liabilities66.08B59.43B61.95B63.16B65.36B
Common Stock387M387M388M388M388M
Retained Earnings1.71B(574M)4.52B3.16B10.97B
Accumulated OCI00000
Other Stockholders Equity1.89B1.92B(1.9B)1.86B2.04B
Minority Interest19M21M23M85M52M
Total Equity39.29B37.06B39.17B40.87B48.72B
Total Debt30.69B29.14B28.62B30.11B29.7B
Net Debt24.36B22.98B22.78B24.63B23.99B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.